FDA Expedites Approval Pathway for Neurizon Therapeutics' ALS Drug NUZ-001

The U.S. Food and Drug Administration (FDA) has informed Neurizon Therapeutics that a single positive pivotal study could support the traditional approval of its lead drug, NUZ-001, for Amyotrophic Lateral Sclerosis (ALS). The company has completed enrollment for its Phase 2/3 HEALEY ALS Platform Trial ahead of schedule, marking the fastest enrollment for any regimen in the trial's history.